Traumatic brain injury (TBI), characterized by acute neurological dysfunction, is one of the best known environmental risk factors for chronic traumatic encephalopathy and Alzheimer's disease, the defining pathologic features of which include tauopathy made of phosphorylated tau protein (P-tau). However, tauopathy has not been detected in the early stages after TBI, and how TBI leads to tauopathy is unknown. Here we find robust cis P-tau pathology after TBI in humans and mice. After TBI in mice and stress in vitro, neurons acutely produce cis P-tau, which disrupts axonal microtubule networks and mitochondrial transport, spreads to other neurons, and leads to apoptosis. This process, which we term 'cistauosis', appears long before other tauopathy. Treating TBI mice with cis antibody blocks cistauosis, prevents tauopathy development and spread, and restores many TBI-related structural and functional sequelae. Thus, cis P-tau is a major early driver of disease after TBI and leads to tauopathy in chronic traumatic encephalopathy and Alzheimer's disease. The cis antibody may be further developed to detect and treat TBI, and prevent progressive neurodegeneration after injury.
Traumatic brain injury (TBI)
is the leading cause of death and disability in children and young adults 1 , and in the USA approximately 2.5 million people suffer TBI each year 2 . Nearly 20% of the 2.3 million troops deployed by the military have sustained TBI 3 . Repetitive mild TBI (rmTBI), seen in contact sports, or even single moderate/severe TBI (ssTBI), seen in military blasts, may cause acute and potentially long-lasting neurological dysfunction, including the development of chronic traumatic encephalopathy (CTE) [4] [5] [6] [7] [8] [9] . TBI is also an established environmental risk factor for Alzheimer's disease [7] [8] [9] [10] [11] [12] . However, no treatment is currently available to prevent CTE or Alzheimer's disease.
CTE is characterized by neurofibrillary tangles made of hyperphosphorylated tau [4] [5] [6] [7] [8] [9] . Such tangles are also a hallmark of Alzheimer's disease and related neurodegenerative disorders, collectively termed tauopathies 13, 14 . Tauopathy spreads in brains [15] [16] [17] [18] [19] and is reduced by immunotherapy against tauopathy epitopes [20] [21] [22] . However, since little tauopathy is detectable acutely or subacutely after TBI in humans and mice 5,7-9, [23] [24] [25] , whether tauopathy is a cause or consequence of posttraumatic neurodegeneration is unknown.
We have identified a unique proline isomerase, Pin1, that inhibits tauopathy in Alzheimer's disease by converting the phosphorylated Thr231-Pro motif in tau (P-tau) from cis to trans in Alzheimer's disease cell and mouse models [26] [27] [28] [29] [30] [31] [32] [33] [34] . In human Alzheimer's disease, Pin1 is inhibited by multiple mechanisms 27, 29, [35] [36] [37] , whereas the Pin1 genetic polymorphism that prevents its downregulation is associated with delaying Alzheimer's disease age of onset 38 . In addition, Pin1 is located at a locus associated with late-onset Alzheimer's disease 39 , P-tau appears early in pre-tangle Alzheimer's disease neurons 40 , and its cerebrospinal fluid level correlates with memory loss in mild cognitive impairment and Alzheimer's disease 41 . We have developed antibodies that distinguish cis from trans P-tau and discovered that trans P-tau is physiological, promoting microtubule assembly, whereas the cis form is early pathogenic, leading to tauopathy in Alzheimer's disease 42 . Currently, it is unknown whether cis P-tau is present after TBI and if so, how to specifically eliminate it.
Robust cis P-tau in human CTE brains
We generated mouse monoclonal antibodies (mAbs) that, like our polyclonal antibodies 42 , were able to distinguish cis from trans tau. We identified a cis mAb clone, 113, and a trans mAb clone, 25, with no cross-reactivity (Extended Data Fig. 1a, b) . Both clones reacted to a pT231-tau peptide, but not its non-phosphorylated counterpart (Extended Data Fig. 1a, b) .
We determined antibody binding affinities using a Biacore assay. Cis and trans mAbs specifically recognized the P-tau peptide (Fig. 1a,  b) , with their binding constants (K D ) being 0.27 and 42.1 nM, respectively (Table 1) . Their IgG isotypes were IgG2b and IgG1, respectively (Extended Data Fig. 1c ). Immunofluorescence and immunoblotting analyses showed robust cis signals in the soma and neurites, and trans signals in the soma in tau-transgenic mice, but not in tau-null mice (Extended Data Fig. 1d, e) . Thus, cis and trans mAb behave similarly to their polyclonal counterparts 42 . Since the T231-tau phospho-epitope is identical among species, we performed double immunofluorescence with cis and trans mAbs on CTE brain tissues from 16 patients with a history of TBI exposure and 8 healthy controls 6 (Supplementary Table 1 ). While trans mAb detected a few neurons in the soma in control and CTE brains, cis mAb detected no signal in control brains. However, robust cis mAb signals were observed in diffuse neurites in all CTE brains examined, with two typical patterns evident, distinguished by one with stronger cis P-tau signals, especially in soma (Fig. 1d , e and Extended Data Fig.  1f-h ). Cis mAb co-localized with AT180 (recognizing pT231-tau), T22 (tau oligomers 43 ), AT8 (early tangles), and AT100 and Alz50 (mature tangles), but trans mAb did not co-localize with T22 (Extended Data Fig. 2a, b) . Cis P-tau was more concentrated near blood vessels (Extended Data Fig. 2c ), as expected 6 . Cis P-tau colocalized diffusely with the axonal marker tau, but not the dendritic marker MAP2, in CTE brains (Fig. 1g, h and Extended Data Fig. 2d ). Thus, cis P-tau localizes primarily to diffuse axons in CTE brains.
Cis P-tau is the earliest TBI tau epitope
To determine the temporospatial characteristics of cis P-tau induction after TBI, we used TBI mouse models induced by impact 25 and blast 5 , modelling sport-and military-related TBI, respectively. 48 h after impact TBI, cis, but not trans, P-tau was elevated in a severity-dependent manner, correlating with total tau (Fig. 2a, b and Extended Data Fig. 3a, b) , and reflecting the stability of cis P-tau 42 . While single mild TBI (mTBI) moderately and transiently induced cis P-tau, which returned to the baseline by 2 weeks, ssTBI robustly and persistently induced cis P-tau, starting at 12 h and peaking at 48 h, but sustaining high levels over time (Fig. 2c, d and Extended Data Fig. 3c ). Both rmTBI and blast TBI also induced robust and persistent cis P-tau induction, with more profound effects in the latter (Fig. 2e, f and Extended Data Fig. 3c ).
Robust cis P-tau signals were detected 48 h after TBI without tau oligomers, aggregation or tangle epitopes (Extended Data Fig. 3d , e, and see results later). Cis P-tau localized mainly to axons, but not dendrites in impact and blast TBI models (Fig. 2g-i) , as in CTE brains (Fig. 1g, h and Extended Data Fig. 2d ). Cis P-tau expression was associated with axonal injury with marked disruption of microtubules and mitochondria, which was notably absent in dendrites (Fig. 2j) Figure 1 | Robust cis, but not trans, P-tau at diffuse axons in human CTE brains. a, b, Cis (a) or trans (b) mAb were immobilized on a sensor chip CM5 for surface plasmon resonance and their binding to pT231-or T231-tau peptide at different concentrations were recorded by SRP sensorgrams. c-h, The frontal cortex of neuropathologically verified human CTE brains and normal controls were subjected to double immunofluorescence with cis (red) or trans (green) mAbs (c-e), n 5 16 for CTE and 8 for controls, or with cis pT231 (red) and the axonal marker tau (green), along with DNA dye (blue) (f-h), n 5 4. Two typical cis P-tau immunostaining patterns are presented, with all cases being shown in Extended Data Fig. 1f , g. Arrows, colocalization; scale bars, 20 mm. 45 Figure 2 | While mTBI has moderate and transient effect, rmTBI, ssTBI or blast TBI leads to robust and persistent cis P-tau induction, notably in diffuse axons starting at 12-24 h. a, b, Mice were subjected to single TBI by a 54 g weight drop from varying heights, followed by immunoblotting (a) and immunofluorescence (b) to detect cis and trans P-tau 48 h later. Cis, red; trans, green; DNA, blue. c-e, Mice were subjected to single mTBI (c), ssTBI (d) or rmTBI (e), followed by immunofluorescence to detect cis and trans P-tau at different times after last injury. n 5 4. f, Mice were subjected to blast-induced TBI, followed by immunofluorescence to detect cis and trans P-tau at different times. n 5 3. g-i, ssTBI (g), rmTBI (h) and blast TBI (i) brain sections at 48 h after last injury were subjected to double immunofluorescence with cis pT231 (red) and axon marker neurofilament SMI312 (green) or dendrite marker MAP2 (green), along with DNA dye (blue). n 5 4. Arrows, colocalization; magnification in b-f, 363; scale bars in g-i, 20 mm. j, ssTBI or sham mice were subjected to electron microscopy analysis 48 h after injury to examine the structure of microtubules (filled arrows) and mitochondria (open arrows) at axons and dendrites. Scale bars, 100 nm.
RESEARCH ARTICLE
G2015 Macmillan Publishers Limited. All rights reserved consistent with the fact that TBI mainly affects axons 44 . Thus, robust cis P-tau is induced acutely in axons after impact and blast TBI long before other forms of P-tau appear.
Cis P-tau spreads and is toxic after TBI Further analysis showed cis P-tau spreading in the brain after TBI. Cis P-tau was mainly limited to the cortex from 24 h to 2 months after rmTBI, but 6 months after rmTBI, robust cis P-tau signals were detected in the cortex and other brain regions, including the hippocampus (Fig. 3a-c) . Marked cis P-tau spread from the cortex to the hippocampus and even to the other side of the brain was observed after blast TBI (data not shown). To examine whether cis P-tau might be neurotoxic, brain lysates prepared from rmTBI and sham mice 6 months post-injury were added to growing cultured neurons overnight. Cis, but not trans, P-tau was readily detected in neurons treated with rmTBI lysates, but not when treated with sham controls (Fig. 3d) . Compared with untreated or sham-treated controls, neurons treated with rmTBI lysates had much higher rates of apoptosis, which was rescued by immunodepletion of total tau or cis, but not trans, mAb (Fig. 3e) . Thus, after impact and blast TBI, cis P-tau is robustly induced, spreads through the brain over time, and induces apoptosis that is blocked by cis mAb.
Stress induces cis P-tau, blocked by mAb
To understand how cis P-tau induces apoptosis and spreads through the brain, we examined the in vitro response to neuronal stress induced by serum starvation or hypoxia. Both conditions induced cis, but not trans, P-tau ( Fig. 4a and Extended Data Fig. 4a, d ), well before tau aggregation (Extended Data Fig. 4e ). The addition of Figure 3 | Cis P-tau spreads in the brain after rmTBI, and spreads and causes neurotoxicity after neuronal stress in vitro, which are fully blocked by cis, but not trans, mAb. a-c, 24 h or 6 months after rmTBI, mouse brains were subjected to immunofluorescence (a, b) and immunoblotting (c) to detect cis P-tau in different brain regions. n 5 4. d, e, Mouse brain lysates prepared from 6-month-post-rmTBI or sham controls were added to culture media of SY5Y neurons for 17 h directly or after immunodepletion with cis or trans mAb, followed by immunofluorescence with cis and trans mAbs or annexin V FACS. n 5 3. f, SY5Y neurons stably expressing GFP-tau or RFP-tau were co-cultured and then treated with hypoxia or control in the presence or absence of cis or trans mAb for different times, followed by assaying cells expressing both GFP-tau and RFP-tau (mean 6 s.d.). P values, two-way ANOVA test. g, h, Primary mouse neurons were transfected with GFP-tau or RFP-tau, and then subjected to hypoxia treatment in the absence or presence of cis or trans mAb for 36 h. The resulting filtered soluble media from GFP-expressing neurons was added to RFP-expressing neurons (g) or vice versa (h), followed by detecting entry of added tau. t a u t a u + c is t a u + t r a n s t a u (T 2 3 1 A ) t a u t a u + c is t a u + t r a n s t a u (T Figure 4 | Stressed neurons robustly produce cis P-tau leading to cistauosis, which is blocked by cis mAb, but enhanced by trans mAb. a, SY5Y cells were cultured without serum for different times in the absence and presence of cis or trans mAb, followed by immunoblotting for cis and trans P-tau. b, SY5Y and differentiated PC12 cells were treated with hypoxia in the absence and presence of cis or trans mAb for 48 h, followed by staining for microtubules. c, Differentiated PC12 cells were treated with hypoxia in the absence and presence of cis or trans mAb for 48 h, followed by live-cell microscopy to capture fast and slow transport of mitochondria along neurites. d-g, SY5Y cells were cultured without serum for different times in the absence and presence of cis or trans mAb, followed by live/dead cell assay (d, e) and apoptosis assays using PARP cleavage (f) and annexin V (g). h, i, SY5Y cells were co-transfected with GFP-tau or GFP-tau(T231A) and p25/Cdk5, followed by live-cell imaging to observe cell death of GFP-tau expressing cells over 65 h (h), with quantification being shown (i) (mean 6 s.d.)
. P values, ANOVA test.
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stressed neuron lysates to neurons induced cell death, which was rescued by immunodepletion with cis, but not trans, mAb, as detected by the live/dead assay (Extended Data Fig. 4g ). To examine whether cis P-tau is implicated in tau spreading, we generated SY5Y cells stably expressing green or red fluorescent protein-conjugated tau (GFP-tau or RFP-tau), and co-cultured them with or without stress. Without hypoxia, neurons continued to express either GFP-tau or RFP-tau, but rarely both proteins ( Fig. 3f and Extended Data Fig. 5b ). However, consistent with cis P-tau spreading in TBI brains (Fig. 3a-c and Extended Data Fig. 5a ), hypoxia induced cis P-tau (Extended Data Fig. 4d ) and caused progressive tau spreading, which was prevented by cis, but not trans, mAb ( Fig. 3f and Extended Data Fig. 5b ). Moreover, serum-starved neurons released cis, but not trans, P-tau at 40 h before neuronal death at 72 h (Extended Data Fig. 4h ). Similar patterns of cis P-tau spread and neurotoxicity were also observed in primary neurons and blocked by cis, but not trans, mAb (Fig. 3g , h, Extended Data Fig. 5c, d ). Thus, toxic cis P-tau is induced and spreads after neuronal stress, similar to TBI.
Cis mAb blocks cistauosis after stress
Given the ability of cis mAb to block tau from spreading and inducing apoptosis, we examined whether cis or trans mAb could affect intracellular P-tau after stress. Indeed, cis mAb entered neurons and effectively blocked time-dependent cis P-tau induction, without affecting trans following serum starvation ( Fig. 4a and Extended Data Fig. 4a ) or hypoxia (Extended Data Fig. 4d ). Conversely, trans mAb reduced trans, but not cis, P-tau ( Fig. 4a) , indicating that the two isomers are not readily interchangeable, as suggested in TBI (Fig. 2) or CTE ( Fig. 1) , and Alzheimer's disease 42 . Since Pin1 inhibition by downregulation 27, 29 , C113 oxidization 35 and S71 phosphorylation 36, 37 contributes to tauopathy in Alzheimer's disease, we asked whether such Pin1 inhibition contributes to cis P-tau induction after stress. Cis induction correlated highly with Pin1 downregulation after serum starvation and Pin1 C113 oxidization after hypoxia (Extended Data Fig. 6a, b ). Pin1 S71 phosphorylation was also markedly elevated in TBI brains (Extended Data Fig. 6c ). Moreover, Pin1 knockdown enhanced cis P-tau induction by hypoxia, which was eliminated by cis mAb (Extended Data Fig. 6d ). Since Pin1 knockout induces P-tau accumulation only in old mice 29, 32, 42 and stress activates Pro-directed kinases, increased tau phosphorylation may be also important for cis P-tau induction after stress or TBI.
Given the ability of cis mAb to ablate intracellular cis P-tau, we evaluated how cis mAb might enter neurons to remove cis P-tau. Tau mAbs enter neurons via Fcc receptors 45 and mAbs trigger targeted protein degradation by the TRIM21-mediated proteasome pathway 46 . Indeed, blocking Fcc receptors prevented cis mAb from binding to or entering neurons (Extended Data Fig. 7a-c) . Immunogold electron microscopy showed cis mAb on the outer cell surface and in intracellular vesicles (Extended Data Fig. 7d ). TRIM21 knockdown 46 , but not the autophagy inhibitor 3-methyladenine (3-MA), prevented cis mAb from ablating cis P-tau (Extended Data Fig. 7e-g ). Thus, cis mAb likely enters neurons via Fcc receptors to target cis P-tau degradation.
To examine the functional significance of neuronal cis P-tau induction and elimination, we investigated whether cis P-tau might affect the microtubule network and function since cis, but not trans, P-tau loses its microtubule function 42 . Hypoxia not only induced cis P-tau (Extended Data Fig. 4d ), but also caused microtubule collapse in neurites, an effect that was rescued by cis, but not trans, mAb ( Fig. 4b and Extended Data Fig. 4b ). Measuring mitochondria movement along neurites showed that hypoxia stopped microtubule-based fast transport, but not actin-based slow movement ( Fig. 4c and Supplementary Videos 1, 2). This mitochondria transport defect was restored by cis mAb, but not trans mAb ( Fig. 4c and Supplementary Video 3), with the latter even causing neurite retraction (Supplementary Video 4), probably by trans-associated promotion of microtubule assembly 42 .
Serum starvation led to robust apoptosis by the time cis P-tau was highly induced, which was potently rescued by cis, but not trans mAb, as detected by a live/dead assay (Fig. 4d , e), PARP cleavage ( Fig. 4f and Extended Data Fig. 4c ) and annexin V fluorescence activated cell sorting (FACS; Fig. 4g ). Similar results were obtained with hypoxia (Extended Data Fig. 4f ), even in primary neurons (Extended Data Fig. 5c, d ). Thus, neuronal stress robustly induces cis P-tau, which disrupts axonal microtubules and organelle transport, spreads to other neurons and leads to apoptosis. These phenotypes, potently rescued by cis but not trans mAb, are here termed 'cistauosis'.
To determine the importance of cis P-tau for neurotoxicity, we co-transfected neurons with GFP-tau or its T231A mutant and p25/Cdk5 phosphorylating tau on Thr231 and others 27, 47 . Co-expression of tau, but not its T231A mutant, with p25/Cdk5 increased cis P-tau, which was eliminated by cis mAb (Extended Data Fig. 8a ). Importantly, most GFP-tau-, but not GFP-tau(T231A)-expressing cells were dead by 62 h, which was markedly blocked by cis mAb, but accelerated by trans mAb (Fig. 4h, i and Supplementary Videos 5, 6). Thus, cis P-tau is necessary and sufficient for P-tau to induce neurotoxicity.
Cis mAb potently treats TBI and CTE
To evaluate the efficacy of cis mAb in treating TBI in vivo, we showed that cis or trans mAb were detected in brains 3 days after peripheral administration (Extended Data Fig. 9a ). After treating ssTBI mice with cis mAb or IgG isotype control for 2 weeks, cis mAb effectively eliminated cis P-tau induction, both with and without pre-treatment ( Fig. 5a and Extended Data Fig. 9b, d) , and also potently reversed post-TBI ultrastructural pathologies of axonal microtubules and mitochondria ( Fig. 5c and Extended Data Fig. 9f ), defective cortical axonal long-term potentiation (LTP) (Fig. 5d and Extended Data Fig.  9g ), and even apoptosis (Extended Data Fig. 9c ), which is observed after TBI even in humans 48 . To determine the impact of cis mAb on behavioural or functional outcomes after TBI, we treated ssTBI mice with cis mAb for 2 months. There was no difference in hippocampal-dependent spatial memory between IgG and cis mAb-treated TBI mice (Extended Data Fig. 9h ). However, as cis P-tau was concentrated in the medial prefrontal cortex at this time point (Fig. 3a) , we used the elevated plus maze, an innate anxiety/risk-taking paradigm that involves cortical circuitry 49 and is affected by TBI 50 . All groups moved similar distances and times in the decision arm ( To examine the effects of cis mAb on tauopathy development and spread, and brain atrophy, hallmarks of CTE 7-9 , we treated ssTBI mice with cis mAb for 6 months. Cis mAb effectively prevented tauopathy development and spread, as assayed by cis P-tau, tau oligomers, aggregation and tangle epitopes (Fig. 5a , b, g, h and Extended Data Figs 9d, e and 10d, e), and brain atrophy in the cortex and white matter ( Fig. 5i and Extended Data Fig. 10f ). Thus, cis mAb not only eliminates cis P-tau and cistauosis, but also prevents tauopathy development and spread, restores LTP and behavioural defects, and prevents brain atrophy after TBI (Fig. 5j) .
Discussion
Here we used cis P-tau mAbs to demonstrate the presence of, and specifically eliminate, pathogenic cis P-tau in clinically relevant in vitro and in vivo models of sport-and military-related TBI. We detected robust cis P-tau signals after sport-and military-related TBI in humans and mice, and in stressed neurons. Following TBI or RESEARCH ARTICLE G2015 Macmillan Publishers Limited. All rights reserved neuronal stress, cis P-tau induces cistauosis well before previously identified tauopathy is apparent. Treating TBI mice with cis mAb ablates cis P-tau and eliminates cistauosis, prevents the development of widespread tauopathy and restores histopathological and many functional outcomes of TBI. Cistausosis is an early precursor of previously described tauopathy and an early marker of neurodegeneration that can be blocked by cis mAb. We previously showed that cis P-tau has an early pathological role in Alzheimer's disease [27] [28] [29] [30] [31] [32] [33] [34] 42 . Our current data provide a direct link from TBI to CTE and Alzheimer's disease, and suggest that cistauosis is a common early disease mechanism in TBI, CTE and Alzheimer's disease, and that cis P-tau and its mAb may be useful for early diagnosis, prevention and therapy for these devastating diseases (Fig. 5j) .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. blocks early cistauosis, prevents tauopathy development and spread, and improves histopathological and functional outcomes. a, b, ssTBI mice were treated with cis mAb or control IgG for times indicated, along sham mice as controls, followed by immunoblotting to detect cis P-tau (a), and sarcosyl extraction to detect tau aggregation (b). TG, transgenic; n 5 4. c, d, After 2 week's treatment, ssTBI mice were subjected to electron microscopy for axonal structures of microtubules (yellow arrows) and mitochondrias (red arrows) (c) or cortical fSPSP recording (d) (mean 6 s.e.m.). Black arrow, theta-burst application; n 5 15 slices from 9 sham; n 5 9 slices from 5 IgG or cis mAb mice. P values, one-way ANOVA with Bonferroni post hoc test. e, f, After 2 month's treatment, ssTBI mice were subjected to the elevated plus maze (e) and time spent in three arms was measured (f) (mean 6 s.e.m.). n 5 4 for sham; n 5 7 for IgG or cis mAb. P values, Student's t-test. g, h, After 2 week's or 6 month's treatment, ssTBI mice were subjected to immunofluorescence with tauopathy mAbs (g), with quantification in the hippocampus being shown (h) (means 6 s.d.). n 5 4. i, After 6 month's treatment, ssTBI mice were immunostained with NeuN before determining brain thickness. n 5 4. j, Unlike single mTBI, rmTBI or ssTBI causes robust and persistent cis P-tau induction within 12-24 h post-injury, which induces cistauosis, long before commonly known tauopathy and brain atrophy, hallmarks of CTE and Alzheimer's disease. Cis mAb not only blocks early cistauosis, but also prevents long-term neurodegeneration after TBI.
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METHODS
Mouse mAb production. Cis and trans mouse mAbs were produced using the general strategy that we used to generate polyclonal cis and trans antibodies, as described 42 . Briefly, Balb/c female mice (2-3 months old) obtained from the Jackson Laboratories (Bar Harbour, ME) were immunized with 100 mg of pThr231-Homoproline (pThr231-Pip) tau peptide (CKKVAVVRpT(Pip) PKSPSSAK) that was coupled to KLH with N-terminal Cys mixed with complete Freund's adjuvant and boosted twice. The titration of antibody production was monitored using ELISA. When sufficient titration of antibody was produced, splenocytes were isolated and fused with SP2/0 myeloma cells to produce hybridoma cell lines, followed by screening for positive clones using ELISA for cis and trans mAbs. When positive clones were identified, they were subcloned by a limited dilution to generate single pure clones. mAbs were produced by injecting 2 ml of 2.5 3 10 6 cells per ml hybridoma cells into nude mice intraperitoneally to collect ascites, followed by purifying mAbs from ascites using antibody purification kit (Pierce) and their specificity were fully characterized. All these animal experiments were approved by Beth Israel Deaconess Medical Center IACUC and complied with the NIH Guide for the Care and Use of Laboratory Animals. ELISA assays. ELISA assays were performed using wild-type phosphorylated Thr231-Pro tau (KVAVVRpTPPKSPS), non-phosphorylated Thr231 tau (KVAVVRTPPKSPS), cis locked phosphorylated Thr231-Dmp tau (KVAVV RpT(5,5-dimethyl-L-proline)PKSPS) and trans lock phosphorylated Thr231-Ala tau (P232A)(KVAVVRpTAPKSPS) peptides, as described 42 . Briefly, peptides at various concentrations in 2,2,2-trifluoroethanol (50 ml) were plated onto maxi soap ELISA plate and dried up at 37 uC overnight. After blocking with buffer containing 5% milk, 0.4% bovine serum albumin and 0.05% Tween 20 in Trisbuffered saline, the cis or trans mAbs at various dilutions in 5% milk, 0.4% bovine serum albumin and 0.05% Tween 20 in Tris-buffered saline (50 ml) was loaded and incubated at room temperature for 2 h, followed by incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG in 5% milk, 0.4% bovine serum albumin and 0.05% Tween 20 in Tris-buffered saline (50 ml) for 1 h. The ELISA plates were washed 4 times with buffer containing 0.4% BSA and 0.05% Tween 20 in TBS after each step. The signals were detected by incubating with TMB substrate solution and were measured by Wallac 1420 software at 450 nm. Surface plasmon resonance. Surface plasmon resonance experiments were performed on a BIAcore 3000 surface plasmon resonance instrument (GE Healthcare-BIAcore) as described by the manufacturer. Briefly, Biacore sensor chip CM-5 was activated by using EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) and NHS (N-hydroxysuccinimide) in a 1:1 ratio for 7 min. Antimouse IgG (Fc) (GE healthcare) was immobilized at pH 5 on flow cells 1 and 2, followed by the capture of 3.7 mg ml 21 of cis or trans mAb in 10 mM sodium acetate with a flow rate of 5 ml min
21
. Then all tau peptides were injected at different concentrations in filtered, degassed 0.01 M HEPES buffer, 0.15 M NaCl, 0.005% surfactant P20, pH 7.4 at a flow rate of 50 ml min 21 for 3 min on both flow cells 1 and 2 and allowed to dissociate for 10 min. All samples were run in duplicate. After each run with a single antibody concentration, the surface was totally regenerated by10 mM glycine pH 1.7 flow late 10 ml min 21 for 5 s. Data analysis was performed by using BIAevaluation software (GE healthcareBIAcore). Immunoblotting analysis and immunodepletion experiment. Immunoblotting analysis was carried out as described 42 . Briefly, brain tissues or culture cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP 40, 0.1% SDS, 0.5% Na-deoxycholate, 50 mM NaF) containing proteinase inhibitors and then mixed with the SDS sample buffer and loaded onto a gel after boiling. The proteins were resolved by polyacrylamide gel electrophoresis and transferred to PVDF membrane. After blocking with 5% milk in TBST (10 mM Tris-HCl pH 7.6, 150 mM NaCl, 0.1% Tween 20) for 1 h, the membrane was incubated with primary antibodies (cis and trans mAbs), Tau5 (Biosource Camarillo, CA), a-tubulin (Sigma, St. Louis, MO) and b-actin antibodies (Sigma, St Louis, MO) in 5% milk in TBST overnight at 4 uC. Then, the membranes were incubated with HRP-conjugated secondary antibodies in 5% milk in TBST. The signals were detected using chemiluminescence reagent (Perkin Elmer, San Jose, CA). The membranes were washed 4 times with TBST after each step. To deplete cis or trans P-tau from lysates, brain or cell lysates were mixed with the cis or trans mAb antibody at 425 mg ml 21 in RIPA buffer containing proteinase inhibitors for 3 h at 4 uC and then mixed with protein A/G Sepharose for 1 h at 4 uC, followed by collecting the supernatants for experiments. The supernatants were dialysed against phosphate buffer saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 ) overnight before cell culture application. Immunoblotting results were quantified using Quantity One from BioRad. Sarkosyl extraction. Isolation of sarkosyl-insoluble and soluble fractions of cells and brain tissues was performed as described 29, 32, 42 , with slight modifications. Briefly, whole brains of mice were homogenized by polytron in 10 volumes of buffer H (10 mM Tris-HCl (pH 7.5) containing 0.8 M NaCl, 1 mM EGTA, and 1 mM dithiothreitol). The cell extraction was also performed with a convenient amount of buffer H (200 ml per 35 mm culture dish) and sonication. The samples were spun at 100,000g for 30 min at 4 uC. Another 2 ml of buffer H was added to the pellet and the samples were homogenized again by polytron, incubated in 1% Triton X-100 at 37 uC for 30 min. Following the incubation, the samples were spun at 100,000g for 30 min at 4 uC, the pellet was homogenized by polytron on 1 ml of buffer H and was then incubated in 1% sarkosyl at 37 uC for 30 min and spun at 100,000g for 30 min at 4 uC. The supernatant was then collected (sarkosylsoluble fraction). Detergent-insoluble pellets were extracted in 100 ml of urea buffer (8 M urea, 50 mM Tris-HCl (pH 7.5)), sonicated, and spun at 100,000g for 30 min at 4 uC. The supernatant was then collected (sarkosyl-insoluble fraction). The protein concentrations of extracts were determined by BCA assay (Thermo Scientific). Sarkosyl-insoluble and -soluble fractions were run on SDS-PAGE gels. Immunostaining analysis. The primary antibodies used were cis and trans mAb, tau tangle-related mAbs AT180, AT8, AT100 (all from Innogenetics, Alpharetta, GA), oligomeric tau T22 polyclonal antibodies (EMD Millipore, Billerica, MA), PHF1 and Alz50 (gifts from P. Davies), anti-tau rabbit mAb (E178, Abcam) and anti-neurofilament mouse mAb (SMI-312, IgG1, Abcam) for labelling axons, and anti-MAP2 mAb (SMI-52, IgG1, Abcam) for labelling dendrites. Immunofluorescence staining of mouse and human brains was done essentially as described 29, 32, 42 . After treatment with 0.3% hydrogen peroxide, slides were briefly boiled in 10 mM sodium citrate, pH 6.0, for antigen enhancement. The sections were incubated with primary antibodies overnight at 4 uC. Then, biotin-conjugated secondary antibodies (Jackson ImmunoResearch), streptavidin-conjugated HRP (Invitrogen) were used to enhance the signals. For double immunofluorescence staining, the sections were also incubated with and Alexa Fluor 488 or 568 conjugated isotype-specific secondary antibodies (Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature. Manufacturer-supplied blocking buffer (Invitrogen) was used for each reaction. The sections were washed 4 times with TBS after each step. Labelled sections were visualized with a Zeiss confocal microscope. The gain of confocal laser was set at the level where there are no fluorescence signals including autofluorescence in sections without primary antibody but with secondary antibody. Immunostaining images and their colocalization were quantified using Volocity 6.3 from Perkin Elmer and Fiji/ImagJ Coloc 2, respectively. Electronic microscopy. Sham and TBI mouse models treated with either control IgG or cis mAb were perfused with a fixative solution, a mixture of 15% picric acid (13% saturated solution; Sigma, St. Louis, MO, USA), 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA), and 0.1% glutaraldehyde (electron microscopy grade 50% solution; Electron Microscopy Sciences) dissolved in PEM buffer (0.1 M PIPES, pH 7.2, 1 mM EGTA, 1 mM MgCl 2 ). Perfused brains were removed, sliced and kept in the same fixative for further 4 h at 4 uC. The samples were processed for electron microscopic observation as described 51, 52 . Specimens were examined with a JEM-1010 transmission electron microscope (JEOL). For immunogold staining, SY5Y cells were treated with cis mAb for 18 h, trypsinized and collected by centrifugation, followed by fixation with 4% PFA. Samples were dehydrated with ethanol, processed for LR white resin embedding and sectioning, followed by gold staining as described 53 . Human brain specimens. Fixed human brain tissue from the frontal cortex of individuals with neuropathologically verified CTE was provided from the VA-BU-SLI Brain Bank of the Boston University Alzheimer's Disease Center CTE Program, including 16 patients with a history of exposure to TBI and 8 agematched healthy controls (Supplementary Table 1) 6 . Next of kin provided written consent for participation and brain donation. Institutional review board approval for brain donation was obtained through the Boston University Alzheimer's Disease Center, CTE Program, and the Bedford VA Hospital. Institutional review board approval for neuropathological evaluation was obtained through Boston University School of Medicine 6 . Our studies on human samples have been approved by our Institutional Review Boards at Boston University and Beth Israel Deaconess Medical Center Transgenic overexpression and knockout mice. Tau-transgenic mice 54 and tau-knockout mice 55 (Jackson laboratory) in the C57BL/6 background were generated, as described 29, 32, 42 ARTICLE RESEARCH cells (2.5 3 10 5 per ml) were transiently co-transfected with 2.5 mg GFP-tau, 2.5 mg Cdk5 and 2.5 mg p25 with Lipofectamine 2000 (Invitrogen) as described 40 . Cells were treated with cis or trans mAbs at 8.0 mg ml 21 once 4 h after transfection until observation.
Cell viabilities were examined using Live & Dead cell assay kit (Abcam) according to the manufacturer. For apoptosis assay, cells were trypsinized and suspended in a binding buffer (10 mM HEPES, pH 7.4; 140 mM NaCl; 2.5 mM CaCl 2 ), stained with Annexin V (Biolegend 640912) for 15 min and subjected for flow cytometry. Brain or cell extracts were applied to culture SY5Y cells for 18 h and the cell viabilities were examined as described earlier. We performed the cell or brain lysate extraction using RIPA buffer but efficiently dialysed the extracts against PBS for 48 h dialysis with 4 changes of buffer.
Stably overexpressing RFP-or GFP-tau SY5Y cells were routinely generated. Briefly, the plasmids pcDNA3.1-tau-RFP and -GFP constructed through restriction sites and were transfected into SY5Y cells via Lipofectamine 2000. Cells stably expressing tau selected with G418). Equal number of GFP-and RFP-tau expressing cells (2.5 3 10 5 per ml) were cocultured, treated or untreated with either cis or trans mAbs at concentration of 170 mg ml 21 for 18 h before moving into hypoxia chamber.
To test cell or brain lysates, accordingly, we performed the extraction using RIPA buffer but efficiently dialysed the extracts against PBS with a cocktail of protease inhibitors at 4 uC for 48 h dialysis with 4 changes of the buffer. After dialysis, we examined cis tau concentration and conformation with immunoblotting and applied the amount of dialysed lysates similar to the original lysates to culture dishes. SY5Y cells were treated with 3-methyladenine at concentration of 5 mM for 24 h.
Primary neurons were prepared from 17-day-old embryonic mouse brain cerebral cortex of either sex. Neurons were seeded on pre-coated culture dishes (2 3 10 5 per ml). The medium was then changed to neurobasal medium supplemented with B27 (Invitrogen) and 1 mM L-glutamine as described 52 . Neurons were infected with lentivirus coding for either GFP-or RFP-tau for 72 h. Mitochondrial transport assay. PC12 cells were differentiated with NGF (Cell Signaling) at 50 ng ml 21 and cultured for 2 days before stress. They were treated with cis or trans mAbs at 85 mg ml 21 for 18 h and transferred into hypoxia chamber for 48 h more. Then, mitochondria were stained using Mitotracker Green FM (Life technologies) according to manufacturer and observed with a Zeiss confocal microscope for 30 min using an incubation chamber with 5% CO 2 at 37 uC. Fluorescent images of labelled mitochondria in the longest process of each PC12 cell were acquired at intervals of 5 s over a period of 30 min. Individual mitochondrial movements were analysed with ZEN 2008 software (Zeiss). Differences in the position of each mitochondrion between two frames during each 5 s interval were exported to Excel, and they were classified and scored as stationary, fast (.0.05 mm s
) or slow (,0.05 mm s 21 ) movements. Traumatic brain injury. The mouse TBI model was used as previously described 25, 56 . Briefly, male C57BL/6 mice (2-3 months old) obtained from the Jackson Laboratories (Bar Harbour, ME) were randomized to undergo injury or sham-injury. The mice were anaesthetized for 45 s using 4% isoflurane in a 70:30 mixture of air:oxygen. Anaesthetized mice were placed on a delicate task wiper (Kimwipe, Kimberly-Clark, Irving, TX) and positioned such that the head was placed directly under a hollow guide tube. The mouse's tail was grasped. A 54-gram metal bolt was used to deliver an impact to the dorsal aspect of the skull, resulting in a rotational acceleration of the head through the Kimwipe. Mice underwent single severe injury (ssTBI, 60-inch height), singe mild injury (mTBI, 28-inch height), or repetitive mild injuries (rmTBI, 7 injuries in 9 days). Sham-injured mice underwent anaesthesia but not concussive injury. All mice were recovered in room air. Anaesthesia exposure for each mouse was strictly controlled to 45 s. Subsequent behavioural and histopathological testing was conducted in a blinded manner. Blast-induced TBI mouse model was performed as described 5 . Briefly, anaesthetized adult wild-type C57BL/6 male mice were exposed to a single blast or sham blast, removed from the apparatus, monitored until recovery of gross locomotor function, and then transferred to their home cage. Maximum burst pressure compatible with 100% survival and no gross motor abnormalities was ascertained empirically. All these and following animal experiments were approved by the Boston Children's Hospital, Beth Israel Deaconess Medical Center and/or Boston University and IACUC and complied with the NIH Guide for the Care and Use of Laboratory Animals. Antibody treatment of mice. Mice undergoing TBI were randomized to treatment with anti-cis P-tau monoclonal mouse antibody or mouse IgG2b. Mice received 1 dose of cis antibody or IgG2b intraperitoneal pre-treatment (i.p. 200 mg per mouse) 3 days before the injury (which was omitted in some experiments), post-injury treatment with single intracerebroventricular (ICV) treatment (20 mg in 5 microlitres) 15 min after injury, then post-treatment 200 mg i.p. every 4 days for 3 times and analysed brains 14 days later for immunoblotting or fEPSP recording, followed by 200 mg i.p. weekly for another 1.5 months (with a total 2 months of treatment) before the elevated plus maze or the Morris Water Maze in a double-blinded manner. After the above treatment, some mice received further antibody treatment, by 200 mg i.p. biweekly for another 4 months before assaying cis P-tau spread, tau aggregation and tauopathy and brain atrophy at 6 months after ssTBI, as described 29, 32, 42 . For all behavioural tests, experimenters were blinded to injury and treatment status, using colourcoding stored in a password protected computer. Electrophysiology. Mice were anaesthetized with isoflurane (NDC 10019-360-40, Baxter Healthcare Corporation Deerfield, IL, USA) and decapitated. The brains were quickly removed and placed for sectioning in ice-cold treatment artificial cerebrospinal fluid (tACSF) containing (in mM) NaCl 124, KCl 3, NaH 2 PO 4 1.25, NaHCO 3 26, CaCl 2 2, MgSO 4 2, and glucose 10 (pH 7.4, and bubbled with 95% O 2 and 5% CO 2 gas mixture). Cortical slices (thickness 350 mm) were cut with a Vibratome 1000P (Leica VT1000P, Leica Microsystems Inc., Buffalo Grove, IL, USA) and transferred to a chamber with oxygenated tACSF for 90 min at 30 uC before recording.
Field excitatory postsynaptic potentials (fEPSP) were recorded using a multielectrode array recording system (MED64 system) with MED-P5155 probe (AutoMate Scientific, Inc., Berkeley, CA, USA) in this study. After incubation, one cortical slice was positioned in the centre of the MED64 probe (to fully cover the 8 3 8 electrode array) with oxygenated recording ACSF (rACSF) containing (in mM) NaCl 124, KCl 3, NaH 2 PO 4 1.25, NaHCO 3 26, CaCl 2 2, MgSO 4 1, and glucose 10 (pH 7.4) at 30 uC. A fine nylon mesh and a mesh anchor were placed on top of the slice to immobilize the slice during recording. The probe with immobilized slice was connected to two MED64 amplifiers (MED64 Head Amplifier (MED-A64HE1) and Main Amplifier (MED-A64MD1), AutoMate Scientific, Inc., Berkeley, CA, USA). The slice was continuously perfused with oxygenated, fresh rACSF at the rate of 2 ml min 21 using a peristaltic pump (Minipuls 3, Gilson Inc., Middleton, WI).
Data was collected using Mobius software (Mobius 0.4.2). Field potentials were induced by single pulses (0.2 ms) delivered at 0.05 Hz through one planar microelectrode in layer V of cortical slice. We used stimulus intensity sufficient to induce a 50% of the maximal fEPSP slope in all experiments. The fEPSP was recorded from the channels in layer II/III. A stable fEPSP slope for at least 20 min was recorded as baseline. The induction protocol of LTP that we used is 5 Hz theta burst (each burst consists of 4 pulses at 100 Hz). The data were filtered at 10 kHz and digitized at a 20 kHz sampling rate. Data were analysed off line by the MED64 Mobius software. For quantifying the level of LTP, the mean of fEPSP slope (10-40%) within the last 10 min of recording was normalized and expressed as a fold change of the averaged baseline (first 10 min of the baseline). Three successive responses were averaged. Statistics were performed using the number of slices as 'n' value, and one to two slices per animal. P values were calculated using one-way ANOVA with Bonferroni post hoc test. Morris water maze. A Morris water maze (MWM) paradigm was used to evaluate spatial learning and memory as described 25, 57 . Briefly, a white pool (83 cm diameter, 60 cm deep) was filled with water to 29 cm depth. Water temperature was maintained at approximately 24 uC. Several highly visible intra-and extramaze cues were located in and around the pool. The target platform (a round, clear, plastic platform 10 cm in diameter) was positioned 1 cm below the surface of the water. During hidden and visible platform trials, mice were randomized to one of four starting quadrants. Mice were placed in the tank facing the wall and given 90 s to find the platform, mount the platform, and remain on it for 5 s. Mice were then placed under a heat lamp to dry before their next run. Time until the mouse mounted the platform (escape latency) was measured and recorded. Mice that failed to mount the platform within the allotted time (90 s) were guided to the platform by the experimenter and allowed 10 s to become acquainted with its location. Each mouse was subjected to a maximum of two trials per day, each consisting of four runs, with a 45-min break between trials. For visible platform trials, a red reflector was used to mark the top of the target platform. For probe trials, mice were placed in the tank with the platform removed and given 60 s to explore the tank. Noldus Ethovision 9 software tracked swim speed, total distance moved, and time spent in the target quadrant where the platform was previously located. When mice underwent repeat MWM testing, 2 to 3 months or 6 months after their final injury, the platform was moved to a different quadrant than that used previously. Elevated plus maze. The elevated plus maze was used to assess anxiety/risktaking behaviour two months after injury and carried out as described 58 . Briefly, the elevated plus maze consists of two open and two closed arms (30 3 5 cm) extended out opposite from each other from a central platform (decision zone) to create a plus shape. The entire apparatus is raised 85 cm above the floor (Lafayette Instruments). Mice are placed on the centre platform of the maze, facing a closed arm, and allowed to explore the apparatus for Immunohistochemistry. Mice were intracardially perfused with 4% paraformaldehyde at various time points after injury and brains were collected for histopathological outcomes. Serial 20 mm coronal frozen sections from sham and injured brains were cut on a cryostat (Leica) from the anterior frontal lobes through the posterior extent of the dorsal hippocampus. Every 10th section was collected and mounted on slides. Statistical analysis. Experiments were routinely repeated at least three times, and the repeat number was increased according to effect size or sample variation. We estimated the sample size considering the variation and mean of the samples. No animals or samples were excluded from any analysis. Animals were randomly assigned groups for in vivo studies and for mAb treatment experiments in mice, group allocation and outcome assessment were also done in a double blinded manner. For all behavioural tests, experimenters were blinded to injury and treatment status, using colour coding stored in a password protected computer. All data are presented as the means 6 s.d. except behavioural tests where data are presented as the means 6 s.e.m., followed by determining significant differences using the two-tailed Student's t test for quantitative variables or ANOVA test for continuous or three or more independent variables or one-way ANOVA with Bonferroni post hoc test, and significant P values ,0.05 are shown. Figure 2 | Colocalization of cis P-tau with other tau epitopes and its concentration near blood vessels in CTE brains. a, b, Colocalization of cis P-tau with other tau epitopes in CTE brains. CTE brain tissues and healthy controls were stained with cis mAb and AT180, AT8, AT100, Alz50 or T22 antibodies, or trans mAb and T22 antibodies, with two examples being shown (a), and then quantified their colocalization using Coloc 2, with the results being expressed in a percentage (mean 6 s.d.) (b). N.D., not detectable.
Extended Data
c, CTE brain tissues and healthy controls were stained with cis mAb, with two examples being shown. Cis is more prominent near blood vessels, which corresponds to the typical perivascular distribution of P-tau in CTE. d, CTE brain tissues and healthy controls were stained with cis mAb (red) and the dendritic marker MAP2 (green), along with DNA dye (blue). Colours in the text correspond to their fluorescence labels. n 5 4.
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Extended Data Figure 3 | TBI induces cis P-tau in a severity-and timedependent manner long before other known tauopathy epitopes. a-c, Severity-and time-dependent induction of cis P-tau after TBI. Quantification results of Fig. 2a-f . d, Robust cis P-tau signals are detected in neurons 48 h after rmTBI without any other tangle-related tau epitopes. 48 h after rmTBI, brain sections were stained with cis mAb (red) and AT8, AT100 or PHF1 (green). e, Robust cis P-tau signals are detected in neurons 48 h after rmTBI without tau oligomerization, which appear and colocalize with cis P-tau at 6 months after TBI. 48 h or 6 months after rmTBI or sham treatment, brain sections were immunostained with T22 (green) and cis or trans mAb (red). The results in 48 h sham mice were similar to those at 6 months (data not shown). The colocalization of red and green signals was quantified using Coloc-2, with the results being shown in percentages. ND, not detectable. n 5 3-4. The results are expressed as means 6 s.d. and P values determined using the Student's t-test.
Extended Data Figure 4 | Stressed neurons robustly produce cis P-tau, cis P-tau is released from stressed neurons and neurotoxic, but is effectively blocked by cis, but not trans, mAb. a-c, Quantification results of Fig. 4a, b and f, respectively. The results are expressed as means 6 s.d. and P values determined using the two-way ANOVA test (a) and Student's t-test (c). d, Hypoxia induces cis P-tau, which is blocked by cis mAb. SY5Y neurons expressing a control vector were cultured in the hypoxia chamber in the absence or presence of cis or trans mAb for the times indicated, followed by immunoblotting for cis P-tau. e, Hypoxia induces cis P-tau before tau aggregation. SY5Y neurons were subjected to hypoxia for the times indicated, followed by sarkosyl extraction before immunoblotting with Tau5 mAb and quantification. f, Hypoxia induces cell death, which are blocked by cis, but not trans, mAb. SY5Y neurons were cultured in the hypoxia chamber in the absence or presence of cis or trans mAb for the times indicated, followed by live and dead cell assay using the LIVE/DEAD Viability/Cytotoxicity Kit. g, Stressed neuron lysates are neurotoxic, which are neutralized by cis, but not trans, mAb. Cell lysates were prepared from stressed SY5Y neurons and then added to growing SY5Y neurons directly (Control) or after immunodepletion with cis or trans mAb to remove cis or trans P-tau, respectively for 3 days, followed by live and dead cell assay. h, Cis P-tau is released from stressed neurons. SY5Y neurons were cultured in the absence of serum for the times indicated and culture media were collected and centrifuged, followed by analysing the supernatants for cis and trans P-tau with actin as an indicator of cell lysis.
Extended Data Figure 5 | Cis P-tau spreads after rmTBI or neuronal stress, and hypoxia induces cell death in primary neurons, which is blocked by cis mAb. a, Cis P-tau spreads in the brain after rmTBI. Quantification results of Fig. 3c . b, Cis P-tau spreads after neuronal stress. GFP-tau or RFP-tau SY5Y neurons were co-cultured and subjected to hypoxia or control treatment in the presence or absence of cis or trans mAb for different times, followed by assaying cells expressing both GFP-tau and RFP-tau (arrows) to determine tau spreading among cells. The results are expressed as means 6 s.d. and P values determined using the Student's t-test. c, Cis mAb enters primary neurons. Primary neurons were established from mouse embryos and differentiated in vitro and cis mAb was added to culture media, followed by immunostaining with secondary antibodies. d, Hypoxia induces cell death in primary neurons, which is effectively blocked by cis mAb. Primary neurons were cultured in the hypoxia chamber in the absence or presence of cis mAb for 48 h, followed by live (green) and dead (red) cell assay using the LIVE/DEAD Viability/ Cytotoxicity Kit.
Extended Data Figure 6 | Pin1 inhibition by multiple mechanisms contributes to cis P-tau induction after neuron stress and TBI. a, Pin1 is downregulated and correlates with cis P-tau induction after serum starvation. Cells were subjected to serum starvation for times indicated, followed by immunoblotting, with the right panel showing the correlation of Pin1 down regulation with cis P-tau induction from Fig. 4a . b, Pin1 is oxidized and correlates with cis P-tau induction after hypoxia. SY5Y cells were subjected to hypoxia for times indicated, followed by immunoblotting for C113 oxidized Pin1, with the right panel showing the correlation of Pin1 oxidization with cis P-tau induction from Extended Data Fig. 6d . c, Pin1 is inhibited in TBI mouse brains. Mouse brains 48 h after ssTBI were subjected to immunoblotting and quantification for Pin1 and S71 phosphorylated Pin1. d, Pin1 knockdown potentiates the ability of hypoxia to induce cis P-tau. Pin1-knockdown or vector control SY5Y cells were subjected to hypoxia treatment for the times indicated in the presence or absence of cis mAb, followed by immunoblotting and quantification for cis P-tau levels. The results are expressed as means 6 s.d.
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Extended Data Figure 7 | Inhibition of FccR binding blocks cis mAb from entering neurons and TRIM21 KD fully prevented cis antibody from ablating cis P-tau in neurons. a-d, Inhibition of FccR binding potently blocks cis mAb from entering neurons. Cis mAb was added to neurons in the absence or presence of a human FccR-binding inhibitor, followed by detecting the binding of cis mAb to the cell surface by FACS (a), entry of cis mAb into cells by immunofluorescence (b), immunoblotting (c) and electron microscopy after immunogold labelling (d). The FcR binding inhibitor fully blocked cis mAb from binding to the cell surface and entering neurons. Electron microscopy showed that cis mAb bound to the cell surface and endocytic vesicles (red arrows). e, f, TRIM21 knockdown fully prevents cis antibody from ablating cis P-tau in neurons. TRIM21 was stably knocked down in SY5Y neuronal cells using a validated TRIM21 shRNA lentiviral vector and confirmed by real-time RT-PCR analysis of TRIM21 mRNA expression (e). TRIM21 knockdown or vector control SY5Y cells were subjected to hypoxia treatment in the presence or absence of cis mAb and/or 3-methyladenine, an autophagy inhibitor, followed by immunoblotting, followed by quantifying cis P-tau levels normalized actin levels (lower panel) (f). The results are expressed as means 6 s.d.
Extended Data Figure 9 | Cis mAb effectively blocks cis P-tau induction and spread, tau aggregation, and restores neuronal ultrastructures, apoptosis and defective LTP after TBI. a, Peripherally administrated cis and trans mAbs enter neurons in brains. 250 mg of biotinylated cis or trans mAb was injected intraperitoneally or intravenously into B6 mice, followed by detecting the biotinylated cis mAb in brains 3 days later. b, c, Cis mAb effectively blocks cis pT231-tau induction and apoptosis. ssTBI mice were randomly and blindly treated with cis mAb or IgG isotype control, i.c.v. (intracerebroventricular) 20 mg per mouse 15 min after injury, and then i.p. 200 mg every 4 days for 3 times, followed by subjecting brains to immunoblotting for cis P-tau (b) and PARP cleavage (c), with sham as controls. d-f, Cis mAb effectively blocks cis pT231-tau induction and spread, tau aggregation and restores neuronal ultrastructures. ssTBI mice in c-f received additional i.p. 200 mg per mouse 3 day before injury. d, Quantification of immunoblotting in Fig. 5a . e, Quantification of immunoblotting in Fig. 5b . f, Quantification of electron microscopy images in Fig. 5c . n 5 3. The results are expressed as means 6 s.d. and P values determined using Student's t-test. g, Cis mAb treatment of ssTBI mice rescues defective LTP in the cortex. fEPSPs were recorded in the layer II/III by stimulating the vertical pathway (the layer V to II/III) in the cortex. Robust LTP was induced by 5 Hz theta-burst in the cortical slices of sham mice (n 5 15 slices, 9 mice), but was deficient in the cortex of IgG-treated TBI mice (n 5 9 slices, 5 mice). However, LTP magnitude was restored to the control level in cis mAb-treated TBI animals (n 5 9 slices, 5 mice). The representative recordings were presented. h, No significant effects of cis pT231-tau mAb treatment on Morris Water Maze performance. 8 weeks after ssTBI, mice underwent Morris Water Maze (MWM) testing consisting of 4 acquisition trials (hidden platform) daily for 4 days (4 runs per trial), a probe trial, followed by a 3 reversal trials (hidden platform) daily for 3 days. Compared to sham mice, injured mice demonstrated increased latency to find the hidden platform in acquisition and reversal trials (P ,0.001). There was no difference in injured cis mAb mice compared to injured IgG treated mice in acquisition trials (P 5 0.5) or reversal trial (P 5 0.9). For probe trials, injured mice performed similarly to sham mice (P 5 0.7) and injured cis mAb treated mice performed similarly to injured IgG treated mice (P 5 0.2). n 5 4-7. The results are expressed as means 6 s.e.m. and P values determined using ANOVA.
Extended Data Figure 10 | Cis mAb treatment effectively restores risktaking behaviour and prevents tauopathy development and spread as well as brain atrophy after TBI. a-c, Cis mAb treatment effectively restores risktaking behaviour 2 months after ssTBI. Video-tracking data of each of all mice shows that ssTBI mice treated with cis mAb (n 5 7) spent similar and very little time in the open arm compared to sham mice (n 5 4), but much less time than TBI mice treated with IgG2b (n 5 7) (a). Cis mAb-treated ssTBI mice had similar performance to sham in travelling velocity, but IgG2b-treated ssTBI mice travelled a greater velocity in the open arm (b). All three groups travelled similar total distance (c). Results are expressed as mean 6 S.E.M. and P values determined using the Student's t-test. d-f, Cis mAb treatment effectively prevents tauopathy development and spread as well as brain atrophy 6 months after ssTBI. ssTBI mice were treated with cis mAb or IgG control for 2 weeks or 6 months, with sham mice as controls, followed by immunofluorescence with various tauopathy epitopes (d), with immunostaining fluorescence intensity in the cortex and hippocampus being quantified (e), or to NeuN immunostaining for determining the thickness of the cortex and white matter at 6 months after TBI (f). n 5 4.
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